TOP TEN perturbations for NM_000226 (Homo sapiens)

Organism: Homo sapiens
Gene: NM_000226
Selected probe(set): 208188_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of NM_000226 (208188_at) across 5339 perturbations tested by GENEVESTIGATOR:

actinic keratosis study 4 (lesion; baseline) / uninvolved skin sample (baseline)

Relative Expression (log2-ratio):5.4833155
Number of Samples:6 / 5
Experimental actinic keratosis study 4 (lesion; baseline)
Punch biopsies of skin lesions obtained from actinic keratosis (AK) patients before treatment (baseline). The biopsies were formalin fixed and paraffin embedded. Patients were ? 18 years of age and had two to five clinically typical, visible, and discrete AK lesions within a contiguous 25 cm2 area on the upper extremity (dorsum of hands or forearm) and with one additional AK lesion located 1 to 5 cm from the AK treatment area. Further the donors had uninvolved skin area on the inner aspect of the upper arm.
Control uninvolved skin sample (baseline)
Punch biopsies of uninvolved skin obtained from actinic keratosis (AK) patients before treatment (baseline). Samples were taken from cca 25 cm2 area of uninvolved, normal-appearing, aged but non-sun-exposed skin on the inner aspect of the upper arm. The biopsies were formalin fixed and paraffin embedded. Patients were ? 18 years of age and had two to five clinically typical, visible, and discrete AK lesions within a contiguous 25 cm2 area on the upper extremity (dorsum of hands or forearm) and with one additional AK lesion located 1 to 5 cm from the AK treatment area. Further the donors had uninvolved skin area on the inner aspect of the upper arm.

actinic keratosis study 4 (lesion; ingenol mebutate; 2d; 0.05%) / actinic keratosis study 4 (lesion; baseline)

Relative Expression (log2-ratio):-5.0454016
Number of Samples:5 / 6
Experimental actinic keratosis study 4 (lesion; ingenol mebutate; 2d; 0.05%)
Punch biopsies of skin lesions obtained from actinic keratosis patients after 2 days treatment with ingenol mebutate 0.05% gel. Samples were taken one day after the second topical application with ingenol mebutate from cca 25 cm2 treated area. The biopsies were formalin fixed and paraffin embedded. Patients were ? 18 years of age and had 2-5 clinically typical, visible, and discrete AK lesions within a contiguous 25 cm2 area on the upper extremity (dorsum of hands or forearm) and with one additional AK lesion located 1 to 5 cm from the AK treatment area. Further the donors had uninvolved skin area on the inner aspect of the upper arm. ATC code:
Control actinic keratosis study 4 (lesion; baseline)
Punch biopsies of skin lesions obtained from actinic keratosis (AK) patients before treatment (baseline). The biopsies were formalin fixed and paraffin embedded. Patients were ? 18 years of age and had two to five clinically typical, visible, and discrete AK lesions within a contiguous 25 cm2 area on the upper extremity (dorsum of hands or forearm) and with one additional AK lesion located 1 to 5 cm from the AK treatment area. Further the donors had uninvolved skin area on the inner aspect of the upper arm.

actinic keratosis study 1 / skin squamous cell carcinoma study 1

Relative Expression (log2-ratio):4.346097
Number of Samples:10 / 30
Experimental actinic keratosis study 1
Skin biopsy from patients with actinic keratosis (AK). Biopsies of skin tissue from different location were snap frozen with liquid nitrogen upon excision during surgery and stored at -80?C. RNA was extracted from fresh frozen tissue specimens by laser capture microdissection. The AK samples included both immunocompetent and immunosuppressed patients (organ transplant recipients (OTRs) or patient with chronic lymphocytic leukemia) and were estimated to be a minimum 90% enrichment for dysplastic cells.
Control skin squamous cell carcinoma study 1
Primary tumor tissue sample from patients with cutaneous squamous cell carcinoma (cuSCC). Biopsies of tumor tissue from different location were snap frozen with liquid nitrogen upon excision during surgery and stored at -80?C. RNA was extracted from fresh frozen tissue specimens by laser capture microdissection. The cSCC samples included a range of histological diagnoses (well differentiated through to poorly differentiated) from both immunocompetent and immunosuppressed patients (organ transplant recipients (OTRs) or patient with chronic lymphocytic leukemia) and were estimated to be a minimum 90% enrichment for tumor.

IL-22 study 1 / untreated neonatal epidermal keratinocyte sample

Relative Expression (log2-ratio):-3.2678204
Number of Samples:3 / 3
Experimental IL-22 study 1
Normal human epidermal keratinocytes (NHEK) from neonatal foreskin cultured with IL-22 (20 ng/ml) for 96h.
Control untreated neonatal epidermal keratinocyte sample
Untreated normal human epidermal keratinocytes (NHEK) from neonatal foreskin.

vulvar intraepithelial neoplasia study 1 / normal vulva tissue

Relative Expression (log2-ratio):3.18161
Number of Samples:9 / 10
Experimental vulvar intraepithelial neoplasia study 1
Vulva biopsy of vulvar intraepithelial neoplasia (VIN).
Control normal vulva tissue
Vulva biopsy of normal tissue.

IL-24 study 1 / untreated neonatal epidermal keratinocyte sample

Relative Expression (log2-ratio):-2.8320465
Number of Samples:3 / 3
Experimental IL-24 study 1
Normal human epidermal keratinocytes (NHEK) from neonatal foreskin cultured with IL-24 (20 ng/ml) for 96h.
Control untreated neonatal epidermal keratinocyte sample
Untreated normal human epidermal keratinocytes (NHEK) from neonatal foreskin.

actinic keratosis study 4 (lesion; ingenol mebutate; 1d; 0.05%) / actinic keratosis study 4 (lesion; baseline)

Relative Expression (log2-ratio):-2.534006
Number of Samples:6 / 6
Experimental actinic keratosis study 4 (lesion; ingenol mebutate; 1d; 0.05%)
Punch biopsies of skin lesions obtained from actinic keratosis patients after 1 day treatment with ingenol mebutate 0.05% gel. Samples were taken one day after the first topical application with ingenol mebutate from cca 25 cm2 treated area. The biopsies were formalin fixed and paraffin embedded. Patients were ? 18 years of age and had 2-5 clinically typical, visible, and discrete AK lesions within a contiguous 25 cm2 area on the upper extremity (dorsum of hands or forearm) and with one additional AK lesion located 1 to 5 cm from the AK treatment area. Further the donors had uninvolved skin area on the inner aspect of the upper arm. ATC code:
Control actinic keratosis study 4 (lesion; baseline)
Punch biopsies of skin lesions obtained from actinic keratosis (AK) patients before treatment (baseline). The biopsies were formalin fixed and paraffin embedded. Patients were ? 18 years of age and had two to five clinically typical, visible, and discrete AK lesions within a contiguous 25 cm2 area on the upper extremity (dorsum of hands or forearm) and with one additional AK lesion located 1 to 5 cm from the AK treatment area. Further the donors had uninvolved skin area on the inner aspect of the upper arm.

actinic keratosis study 4 (lesion; ingenol mebutate; 2d; 0.05%) / actinic keratosis study 4 (lesion; ingenol mebutate; 1d; 0.05%)

Relative Expression (log2-ratio):-2.5113955
Number of Samples:5 / 6
Experimental actinic keratosis study 4 (lesion; ingenol mebutate; 2d; 0.05%)
Punch biopsies of skin lesions obtained from actinic keratosis patients after 2 days treatment with ingenol mebutate 0.05% gel. Samples were taken one day after the second topical application with ingenol mebutate from cca 25 cm2 treated area. The biopsies were formalin fixed and paraffin embedded. Patients were ? 18 years of age and had 2-5 clinically typical, visible, and discrete AK lesions within a contiguous 25 cm2 area on the upper extremity (dorsum of hands or forearm) and with one additional AK lesion located 1 to 5 cm from the AK treatment area. Further the donors had uninvolved skin area on the inner aspect of the upper arm. ATC code:
Control actinic keratosis study 4 (lesion; ingenol mebutate; 1d; 0.05%)
Punch biopsies of skin lesions obtained from actinic keratosis patients after 1 day treatment with ingenol mebutate 0.05% gel. Samples were taken one day after the first topical application with ingenol mebutate from cca 25 cm2 treated area. The biopsies were formalin fixed and paraffin embedded. Patients were ? 18 years of age and had 2-5 clinically typical, visible, and discrete AK lesions within a contiguous 25 cm2 area on the upper extremity (dorsum of hands or forearm) and with one additional AK lesion located 1 to 5 cm from the AK treatment area. Further the donors had uninvolved skin area on the inner aspect of the upper arm. ATC code:

KGF study 1 / untreated neonatal epidermal keratinocyte sample

Relative Expression (log2-ratio):-2.3844948
Number of Samples:3 / 3
Experimental KGF study 1
Normal human epidermal keratinocytes (NHEK) from neonatal foreskin cultured with KGF (10 ng/ml) for 96h.
Control untreated neonatal epidermal keratinocyte sample
Untreated normal human epidermal keratinocytes (NHEK) from neonatal foreskin.

CBFA2T3 depletion; IKKb(EE) overexpression study 1 / control transfected Reh cell sample

Relative Expression (log2-ratio):2.3301306
Number of Samples:2 / 2
Experimental CBFA2T3 depletion; IKKb(EE) overexpression study 1
Non-Hodgkin?s lymphoma cell line Reh was transiently transfected with pMSCVpuroH1 vector expressing CBFA2T3-silencing shRNA and pRK5 vector overexpressing constitutively active form of I?B kinase ? (IKKb(EE)) along with GFP-expressing vector pEGFP-N3. After 72 hours, GFP-positive cells were FACS-sorted and analyzed.
Control control transfected Reh cell sample
Non-Hodgkin?s lymphoma cell line Reh was transiently transfected with pMSCVpuroH1 vector expressing scramled shRNA and empty pRK5 vector along with GFP-expressing vector pEGFP-N3. After 72 hours, GFP-positive cells were FACS-sorted and analyzed.